Pivotal bioVenture Partners Investment Advisor’s Oculis Holding OCS Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio OCS Stock Details OCS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$44.7M	Sell	1,680,283 -608,375	-27%	-$16.1M	15.97%	2
2025 Q4	$45.7M	Sell	2,288,658 -12,116	-0.5%	-$242K	17.67%	2
2025 Q3	$40.4M	Hold	2,300,774	–	–	23.38%	2
2025 Q2	$44.7M	Hold	2,300,774	–	–	27.68%	1
2025 Q1	$43.8M	Buy	2,300,774 +563,078	+32%	+$11.5M	35.43%	1
2024 Q4	$29.5M	Buy	1,737,696 +141,778	+9%	+$2.23M	19.95%	2
2024 Q3	$19.6M	Hold	1,595,918	–	–	11.61%	4
2024 Q2	$19.1M	Hold	1,595,918	–	–	14.66%	3
2024 Q1	$19.2M	Sell	1,595,918 -292,870	-16%	-$3.51M	12.36%	4
2023 Q4	$21.2M	Sell	1,888,788 -329,966	-15%	-$3.42M	5.38%	3
2023 Q3	$24.4M	Sell	2,218,754 -162,442	-7%	-$2.04M	9.73%	3
2023 Q2	$29.4M	Hold	2,381,196	–	–	9.68%	3
2023 Q1	$17.7M	Buy	+2,381,196	New	+$19.9M	7.29%	4

Other funds holding OCS

EFM

EQT Fund Management Luxembourg $1.02B AUM

Gildi lifeyrissjodur Reykjavik $197M AUM

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's OCS Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor reduced its Oculis Holding (OCS) stake by 27% in Q1 2026, selling an estimated $16.1M and leaving 1,680,283 shares worth $44.7M. The position accounts for 15.97% of the portfolio, ranked #2.

Pivotal bioVenture Partners Investment Advisor first reported a position in OCS in Q1 2023 and has held it in 13 quarters since. The position peaked at $45.7M in Q4 2025. 57 funds tracked by Wall St. Rank hold OCS as of Q1 2026.

Pivotal bioVenture Partners Investment Advisor held 1,680,283 shares of Oculis Holding worth $44.7M as of Q1 2026.
Pivotal bioVenture Partners Investment Advisor sold 608,375 Oculis Holding shares in Q1 2026, an estimated $16.1M.
Oculis Holding made up 15.97% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #2 holding.
Pivotal bioVenture Partners Investment Advisor first reported a position in Oculis Holding in Q1 2023 and has held it in 13 quarters since.
Pivotal bioVenture Partners Investment Advisor's Oculis Holding position peaked at $45.7M in Q4 2025.
57 funds tracked by Wall St. Rank held Oculis Holding as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.